Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
Ugur Sahin, CEO of the German laboratory BioNTech, which works with Pfizer the first international coronavirus vaccine to see if there is a possibility of adapting it to the new strain registered in the UK.
The co-founder of the laboratory indicated that efficacy tests are underway on the variant. Likewise, he explained: Scientifically, it is very likely that the immune response of this vaccine can also cope with the new variants, but we will only know if the experiment is over … we will release the data as soon as possible.
Variant proteins detected in the UK are 99% equal to that of dominant strains. If the formula changes, he commented: In principle, the beauty of messenger technology is that we can start designing a vaccine right away that completely mimics this new mutation. we might be able to technically deliver a new vaccine in six weeks.
Marco Cavaleri, head of the vaccine team at the European Medicines Agency, showed his confidence in the vaccine from Pfizer and BioNTech. And added that should not be affected by the effects of mutations in the new strain, but health officials will start to worry if we see multiple mutations, especially in spike proteins.
Yesterday the World Health Organization (WHO) notes that the transmission of this new variant is between 40% and 70% higher than the previous ones.
.
[ad_2]
Source link
